We are dedicated to developing tomorrow’s drugs against oxidative stress, helping millions of people to a better life by preventing and treating serious kidney diseases. ROSgard, our biological drug candidate, mimics the body’s own powerful defense system against oxidative stress. Designed with a natural “homing” to the kidneys, ROSgard prevents kidney damage by protecting, cleaning and repairing the exposed cells and tissues.

A phase 1 program including three separate studies have been completed during the autumn in 2020. Read more hear about the clinical development of ROSgard.

Read more

CLINICAL STUDIES

ROSgard, our drug candidate, is designed to mimic the body's own defense system against oxidative stress by protecting, cleaning and repairing exposed cells and tissue.

Read more

ROSgard™

Acute kidney injury is a large market. The estimated annual value is USD 6.3 bn in the USA and GBP 500 mn in the UK.

Read more

INVESTOR RELATIONS

Press releases
  • 29 Dec 2020  ·  Regulatory information

    Guard Therapeutics completes successful pre-IND meeting with FDA

    Read more
  • 28 Dec 2020  ·  Regulatory information

    Guard Therapeutics appoints Ann-Kristin Myde as Head of Global Project Management

    Read more
  • 11 Dec 2020  ·  Regulatory information

    Guard Therapeutics receives Notice of Allowance from USPTO for ROSgard

    Read more
  • 28 Sep 2020  ·  Regulatory information

    Guard Therapeutics reports positive top-line results from phase 1 study of ROSgard in individuals with renal impairment

    Read more
Show more
Calendar & reports
  • 24 Feb 2021

    Year-end report 2020

    Read more
  • 12 May 2021

    Interim report January-March 2021

    Read more
  • 12 May 2021

    Annual General Meeting 2021 (including Annual Report 2020)

    Read more
  • 19 Aug 2021

    Interim report April-June 2021

    Read more
Reports & presentations
  • 04 Jun 2020 / Analysis

    Monocl valuation report for cardiac surgery AKI 2018

    Read more
  • 04 Jun 2020 / Analysis

    Redeye valuation report 2019

    Read more
Show more